CEL-SCI’s Phase III Trial Enrols Patients From Sri Lanka

CEL-SCI has begun enrolling patients from Sri Lanka for a Phase III trial for Multikine, an investigational treatment for head and neck cancer.

AsianScientist (Jul 25, 2014) – CEL-SCI Corporation has received clearance from Sri Lanka’s Ministry of Health to commence patient enrollment for its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka.

This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015.

CEL-SCI’s global pivotal Phase III clinical trial is the largest trial for head and neck cancer in the world. The trial, which already has over 220 patients enrolled, is assessing the Company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer.

If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors.

“If Multikine can be proven to harness the immune system against cancer, we believe this could offer a new modality for the treatment of head and neck cancer that could work in concert with the other methods – surgery, chemotherapy, and radiation therapy, used today for the treatment of this debilitating disease.” stated CEL-SCI Chief Executive Officer Geert Kersten.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

———

Source: CEL-SCI Corporation.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist